| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
BIIB
Biogen
|
Jun 18, 2026 | HOLD |
Strong Buy
+25.1% avg upside
51 analysts
|
$224.00
13.89% Upside
|
· |
|
AMGN
Amgen
|
Jun 10, 2026 | HOLD |
Buy
-11.6% avg upside
57 analysts
|
$340.00
0.66% Upside
|
-0.0% |
|
NRIX
Nurix Therapeutics
|
Jun 08, 2026 | BUY |
Strong Buy
+76.3% avg upside
26 analysts
|
$36.00
105.11% Upside
|
· |
|
LLY
Eli Lilly & Co
|
Jun 08, 2026 | BUY |
Strong Buy
-10.5% avg upside
47 analysts
|
$1344.00
22.25% Upside
|
-4.4% |
|
GILD
Gilead Sciences
|
Jun 04, 2026 | BUY |
Strong Buy
-4.8% avg upside
66 analysts
|
$168.00
35.81% Upside
|
-3.6% |
|
UTHR
United Therapeutics
|
Jun 04, 2026 | HOLD |
Buy
-19.0% avg upside
26 analysts
|
$516.00
3.91% Downside
|
+0.7% |
|
ABBV
AbbVie
|
May 31, 2026 | BUY |
Buy
+2.8% avg upside
43 analysts
|
$278.00
28.49% Upside
|
+3.9% |
|
BHVN
Biohaven Ltd.
|
May 28, 2026 | BUY |
Strong Buy
+87.5% avg upside
25 analysts
|
$18.00
32.65% Upside
|
+32.5% |
|
BMY
Bristol-Myers Squibb
|
May 26, 2026 | SELL |
Buy
+9.1% avg upside
42 analysts
|
$40.00
26.02% Downside
|
+4.7% |
|
BNTX
BioNTech SE
|
May 18, 2026 | BUY |
Strong Buy
+50.5% avg upside
26 analysts
|
$126.00
38.67% Upside
|
+2.3% |
|
ALMS
Alumis Inc.
|
May 15, 2026 | BUY |
Strong Buy
+63.6% avg upside
11 analysts
|
$39.00
66.50% Upside
|
+0.8% |
|
LEGN
Legend Biotech
|
May 13, 2026 | BUY |
Strong Buy
+134.2% avg upside
27 analysts
|
$48.00
71.90% Upside
|
+25.1% |
|
PRME
Prime Medicine, Inc.
|
May 13, 2026 | HOLD |
Strong Buy
+210.0% avg upside
16 analysts
|
— | -6.4% |
|
NTLA
Intellia Therapeutics
|
May 13, 2026 | HOLD |
Buy
+153.7% avg upside
37 analysts
|
$15.00
4.21% Downside
|
-15.2% |
|
RCUS
Arcus Biosciences
|
May 11, 2026 | HOLD |
Strong Buy
+38.0% avg upside
20 analysts
|
$22.00
9.43% Downside
|
-3.0% |
|
RPRX
Royalty Pharma
|
May 07, 2026 | BUY |
Strong Buy
+4.2% avg upside
15 analysts
|
$64.00
20.85% Upside
|
+7.4% |
|
PFE
Pfizer
|
May 06, 2026 | HOLD |
Buy
+34.1% avg upside
45 analysts
|
$28.00
11.15% Upside
|
-3.4% |
|
VRTX
Vertex Pharmaceuticals
|
May 05, 2026 | BUY |
Strong Buy
-2.7% avg upside
61 analysts
|
$616.00
36.32% Upside
|
+8.2% |
|
MRK
Merck & Company
|
May 01, 2026 | HOLD |
Strong Buy
+10.7% avg upside
43 analysts
|
$112.00
1.61% Downside
|
+3.7% |
|
MRNA
Moderna
|
May 01, 2026 | HOLD |
Hold
+6.4% avg upside
38 analysts
|
$33.00
48.42% Downside
|
+41.0% |
|
REGN
Regeneron
|
Apr 30, 2026 | HOLD |
Strong Buy
+26.9% avg upside
57 analysts
|
$788.00
29.13% Upside
|
-13.9% |
|
JNJ
Johnson & Johnson
|
Apr 15, 2026 | BUY |
Strong Buy
-3.6% avg upside
36 analysts
|
$283.00
23.86% Upside
|
-0.9% |
|
OGN
Organon
|
Apr 10, 2026 | HOLD |
Sell
+10.6% avg upside
9 analysts
|
$9.00
32.98% Downside
|
+52.2% |
|
ARVN
Arvinas Holding Company
|
Mar 18, 2026 | HOLD |
Buy
+265.4% avg upside
27 analysts
|
$11.00
43.32% Upside
|
-30.4% |
|
GPCR
Structure Therapeutics, Inc. Sponsored ADR
|
Feb 27, 2026 | BUY |
Strong Buy
+132.5% avg upside
17 analysts
|
$126.00
183.14% Upside
|
-41.9% |
|
CRSP
Crispr Therapeutics AG
|
Feb 17, 2026 | SELL |
Buy
+39.7% avg upside
41 analysts
|
$33.00
39.07% Downside
|
-1.7% |
|
CCCC
C4 Therapeutics
|
Sep 21, 2025 | HOLD |
Strong Buy
+341.8% avg upside
19 analysts
|
— | +36.4% |
|
EDIT
Editas Medicine
|
Dec 13, 2024 | HOLD |
Buy
+420.3% avg upside
33 analysts
|
— | +75.7% |
|
ALKS
Alkermes
|
Jun 01, 2021 | SELL |
Strong Buy
-17.5% avg upside
34 analysts
|
$16.00
64.38% Downside
|
-29.5% |
|
CTMX
CytomX Therapeutics
|
Aug 10, 2020 | HOLD |
Strong Buy
+269.4% avg upside
21 analysts
|
$12.00
306.75% Upside
|
-35.6% |
|
DE:MRK
Merck KGaA
|
Aug 03, 2020 | BUY |
Buy
+2.1% avg upside
32 analysts
|
$90.42
32.14% Downside
|
· |
|
TSE:BHC
Bausch Health Companies
|
Dec 02, 2019 | HOLD |
Buy
+783.6% avg upside
29 analysts
|
$41.99
522.99% Upside
|
· |
|
KLDO
Kaleido Biosciences
|
Mar 25, 2019 | BUY |
Buy
+13249900.0% avg upside
5 analysts
|
$20.00
19999899.95% Upside
|
-58.3% |
|
DNTH
Dianthus Therapeutics
|
Mar 25, 2019 | HOLD |
Strong Buy
+8.9% avg upside
29 analysts
|
$16.00
80.67% Downside
|
-67.9% |
|
ALNY
Alnylam Pharma
|
Aug 13, 2018 | BUY |
Strong Buy
+23.4% avg upside
51 analysts
|
$155.00
44.29% Downside
|
-12.0% |
|
KNSA
Kiniksa Pharmaceuticals
|
Jun 18, 2018 | HOLD |
Strong Buy
-0.2% avg upside
11 analysts
|
$22.00
60.08% Downside
|
-22.1% |
|
KYNB
Kyntra Bio
|
Jul 21, 2017 | HOLD |
Buy
+369.6% avg upside
14 analysts
|
$31.00
362.79% Upside
|
+86.1% |
|
AGIO
Agios Pharma
|
Jun 13, 2016 | HOLD |
Strong Buy
+73.8% avg upside
29 analysts
|
$46.00
34.75% Upside
|
-2.4% |
|
ATRA
Atara Biotherapeutics
|
Nov 18, 2015 | HOLD |
Buy
+79.8% avg upside
18 analysts
|
$38.00
277.41% Upside
|
-43.9% |
|
MCRB
Seres Therapeutics
|
Jul 21, 2015 | HOLD |
Buy
+163.4% avg upside
10 analysts
|
$36.00
444.56% Upside
|
-14.0% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.